Global Treatment of Gastric/GEJ Cancer with Durvalumab Plus FLOT
Featuring Yelena Janjigian, MD
At the 2024 ASCO Gastrointestinal Symposium, Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, New York, shared recent data from the MATTERHORN study, evaluating durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy among patients with gastric or gastroesophageal junction cancer (GC/GEJC).
This subgroup analysis found the benefit to pathological complete response (pCR) of adding durvalumab to FLOT among patients with GC/GEJC was seen consistently across all geographic regions.
Source:
Janjigian YY, Al-Batran S, Wainberg ZA, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract LBA246
